Allergy Therapeutics PLC
LSE:AGY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Allergy Therapeutics PLC
Net Issuance of Debt
Allergy Therapeutics PLC
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Net Issuance of Debt
£26.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
142%
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Net Issuance of Debt
£1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
AstraZeneca PLC
LSE:AZN
|
Net Issuance of Debt
$1.2B
|
CAGR 3-Years
85%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-14%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Net Issuance of Debt
$290m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
6%
|
CAGR 10-Years
6%
|
|
|
Animalcare Group PLC
LSE:ANCR
|
Net Issuance of Debt
£14.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Net Issuance of Debt
-£22.1m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-26%
|
|
Allergy Therapeutics PLC
Glance View
Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.
See Also
What is Allergy Therapeutics PLC's Net Issuance of Debt?
Net Issuance of Debt
26.7m
GBP
Based on the financial report for Dec 31, 2025, Allergy Therapeutics PLC's Net Issuance of Debt amounts to 26.7m GBP.
What is Allergy Therapeutics PLC's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
142%
Over the last year, the Net Issuance of Debt growth was -66%.
